These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17685864)

  • 41. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.
    Bilusic M; Gulley JL
    Cancer Immunol Immunother; 2012 Jan; 61(1):109-17. PubMed ID: 22120693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cancer vaccines 2000.
    Tartour E; Fridman WH
    Immunol Lett; 2000 Sep; 74(1):1-3. PubMed ID: 10996621
    [No Abstract]   [Full Text] [Related]  

  • 43. [Cancer immunotherapy--current status].
    Kundig TM; Renner Ch; Knuth A
    Ther Umsch; 2006 Apr; 63(4):262-6. PubMed ID: 16689457
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art.
    Schreiber TH; Raez L; Rosenblatt JD; Podack ER
    Semin Immunol; 2010 Jun; 22(3):105-12. PubMed ID: 20226686
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Active immunotherapy in patients with hematologic and solid neoplasms].
    Mellstedt H; Veelken H
    Onkologie; 2005 Oct; 28 Suppl 4():4-8. PubMed ID: 16285039
    [No Abstract]   [Full Text] [Related]  

  • 46. Anti-idiotype vaccine against cancer.
    Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA
    Immunol Lett; 2000 Sep; 74(1):51-8. PubMed ID: 10996628
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.
    Farkas A; Conrad C; Tonel G; Borbenyi Z; Kemeny L; Dobozy A; Nestle FO
    Skin Pharmacol Physiol; 2006; 19(3):124-31. PubMed ID: 16612139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Immunotherapy of cancer].
    Andersen MH; Schmidt H; Gehl J; von der Maase H; Straten P
    Ugeskr Laeger; 2002 Jun; 164(23):3008-16. PubMed ID: 12082849
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicting analysis times in randomized clinical trials with cancer immunotherapy.
    Chen TT
    BMC Med Res Methodol; 2016 Feb; 16():12. PubMed ID: 26830911
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Current status and future perspective of cancer vaccine development].
    Sasada T; Itoh K
    Gan To Kagaku Ryoho; 2011 Apr; 38(4):503-8. PubMed ID: 21498975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.
    Arlen PM; Wood LV
    Expert Rev Vaccines; 2012 Mar; 11(3):287-302. PubMed ID: 22380822
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlates of immune and clinical activity of novel cancer vaccines.
    van der Burg SH
    Semin Immunol; 2018 Oct; 39():119-136. PubMed ID: 29709421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
    Sosman JA; Sondak VK
    Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
    Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
    Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Perspective on allogeneic melanoma lysates in active specific immunotherapy.
    Mitchell MS
    Semin Oncol; 1998 Dec; 25(6):623-35. PubMed ID: 9865677
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer vaccines inducing antibody production: more pros than cons.
    Jensen-Jarolim E; Singer J
    Expert Rev Vaccines; 2011 Sep; 10(9):1281-9. PubMed ID: 21919618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The clinical development of vaccines for HER2
    Costa RLB; Soliman H; Czerniecki BJ
    Cancer Treat Rev; 2017 Dec; 61():107-115. PubMed ID: 29125981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Approaches to improve development methods for therapeutic cancer vaccines.
    Ogi C; Aruga A
    Immunol Lett; 2015 Apr; 164(2):100-8. PubMed ID: 25746315
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Update on active specific immunotherapy with melanoma vaccines.
    Conforti AM; Ollila DW; Kelley MC; Gammon G; Morton DL
    J Surg Oncol; 1997 Sep; 66(1):55-64. PubMed ID: 9290695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.